Aligos Therapeutics (ALGS) Capital Expenditures (2019 - 2023)

Aligos Therapeutics has reported Capital Expenditures for 5 years, with the latest figure at $7000.0 in Q1 2023.

• For the quarter ending Q1 2023, Capital Expenditures fell 98.64% year-over-year to $7000.0; the trailing twelve-month figure through Mar 2023 stood at $435000.0 (down 60.45% YoY), and the FY2024 full-year result was $130000.0, up 584.21% from the prior year.
• Capital Expenditures for Q1 2023 stood at $7000.0, down from $91000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $2.6 million in Q4 2019, with the low at $3000.0 in Q3 2022.
• Historically, Capital Expenditures has averaged $462785.7 across 5 years, with a median of $320500.0 in 2021.
• Annual changes were most pronounced in 2021 — Capital Expenditures soared 450.82% — and 2023, when it sank 98.64%.
• Aligos Therapeutics' Capital Expenditures stood at $2.6 million in 2019, then sank by 97.63% to $61000.0 in 2020, then soared by 450.82% to $336000.0 in 2021, then tumbled by 72.92% to $91000.0 in 2022, then plunged by 92.31% to $7000.0 in 2023.
• The last three Capital Expenditures figures came in at $7000.0 (Q1 2023), $91000.0 (Q4 2022), and $3000.0 (Q3 2022), per Business Quant data.